Vitamin C increases treatment efficacy when combined with standard-of-care radio-chemotherapy in GBM
Thanks to Ergin for indicating this article "O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate." https://www.ncbi.nlm.nih.gov/pubmed/28366679 published in the Cancer Cell, one of the top scientific peer-reviewed journals reporting major advances in cancer research and oncology. This is a well researched article published in 2017 and co-authored by 35 medical doctors and scientists from USA stating the following:
"Despite advances in treatment strategies, 5-year overall survival in NSCLC and GBM has not significantly increased over the last 20 years. Here, we demonstrate that pharmacological ascorbate represents an easily implementable and non-toxic agent that may increase treatment efficacy when combined with standard-of-care radio-chemotherapy in NSCLC and GBM. Furthermore, the mechanism by which ascorbate is selectively toxic to cancer cells versus normal cells is shown to involve alterations in redox-active iron metabolism mediated by mitochondrial O2- and H2O2. As fundamental defects in oxidative metabolism leading to increased steady-state levels of O2- and H2O2 emerge as targetable hallmarks of cancer cells, the current findings support a generalized mechanism for the application of pharmacological ascorbate in cancer therapy."
The above is an as clear statement as it can get n a scientific setting, coming from 35 medical doctors and scientists.